A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a

Trial Profile

A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MAIN-MS
  • Sponsors Merck KGaA
  • Most Recent Events

    • 06 Jul 2017 Planned End Date changed from 1 Sep 2020 to 30 Sep 2020.
    • 06 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 30 Jun 2018.
    • 15 Feb 2017 Planned number of patients changed from 700 to 824.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top